DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2006/0127486A1 Moerck Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2006/0127486A1 Moerck Et Al US 2006O127486A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0127486A1 Moerck et al. (43) Pub. Date: Jun. 15, 2006 (54) CERAMIC STRUCTURES FOR Related U.S. Application Data PREVENTION OF DRUG DIVERSION (60) Provisional application No. 60/587,662, filed on Jul. (76) Inventors: Rudi E. Moerck, San Antonio, TX 13, 2004. (US); Bruce J. Sabacky, Reno, NV (US); Timothy M. Spitler, Fernley, NV Publication Classification (US); Jan Prochazka, Reno, NV (US); Douglas Ellsworth, Reno, NV (US) (51) Int. Cl. A6II 3L/485 (2006.01) A6IR 9/14 (2006.01) Correspondence Address: (52) U.S. Cl. ........................... 424/489: 514/282; 977/906 SHEPPARD, MULLIN, RICHTER & HAMPTON LLP (57) ABSTRACT 333 SOUTH HOPE STREET 48TH FLOOR The present invention is directed to compositions that pro LOS ANGELES, CA 90071-1448 (US) vide drug delivery while resisting methods of diversion. The compositions are combinations of the drug and a ceramic structure. Any Suitable drug may be used, but the drug is (21) Appl. No.: 11/181,667 typically an opioid agonist. The ceramic structures arc usually metal oxides, and are oftentimes roughly spherical in (22) Filed: Jul. 13, 2005 shape with a hollow center. US 2006/0127486 A1 Jun. 15, 2006 CERAMC STRUCTURES FOR PREVENTION OF nm: 401 nm to 500 nm, 501 nm to 600 nm, 601 nm to 700 DRUG DIVERSION nm: 701 nm to 800 nm: 801 nm to 900 nm:901 mm to 1 um: 1 um to 10 um; 11 um to 25 um; and, 26 um to 100 um. CROSS REFERENCE TO RELATED Variation in particle size is typically less than 10.0% of the APPLICATIONS mean diameter, preferably less than 7.5% of the mean 0001. This application claims priority to U.S. provisional diameter, and more preferably less than 5.0% of the mean patent application No. 60/587,662, the entire disclosure of diameter. which is incorporated by reference. 0009. The ceramic structure typically includes titanium oxide or Zirconium oxide. The included drug is typically an FIELD OF INVENTION opioid agonist selected from oxycodone, codeine, hydroc 0002 The present invention generally relates to the pre odone, hydromorphone, levorphanol, meperidine, meth vention of drug diversion. More specifically, it relates to andone, and morphine. Ceramic structure/drug combina drug? ceramic structure combinations that provide drug tions of the present invention exhibit measurable mechanical delivery while resisting methods of diversion. strength. At least 50 percent of the particles maintain their overall integrity (e.g., shape, size, porosity, etc.) when a BACKGROUND OF INVENTION force of 5 kg/cm, 7.5 kg/cm, 10.0 kg/cm, 12.5 kg/cm, 15.0 kg/cm, 17.5 kg/cm or 20 kg/cm is applied to them. 0003 Drug diversion is the use of a prescribed medica tion by a person for whom the medication was not pre scribed. Such use accounts for almost 30% of drug abuse in DETAILED DESCRIPTION the United States and represents a close challenge to cocaine 0010. The present invention is directed to drug? ceramic addiction. The majority of abusers are persons with no structure combinations that provide drug delivery while history of prior drug abuse who became addicted after using resisting methods of diversion. prescription drugs for legitimate medical reasons. 0011. One can incorporate any suitable drug into the 0004. It is well-known that abusers of prescribed medi combination of the present invention, although opioid ago cation target two parameters when diverting drugs—dose nists are preferred. Such agonists include, without limita amount and dose form for rapid administration. A diverter tion, the following: alfentanil, allylprodine, alphaprodine, will oftentimes obtain a drug, crush it, and then deliver it anileridine, benzylmorphine, bezitramide, buprenolphine, intranasally. Another mode of administration involves dis butorphanol, clonitaZene, codeine, desomorphine, dextro Solving the drug in water or alcohol and then delivering it moramide, dezocine, diampromide, diamorphone, dihydro intravenously. Either delivery mode provides for rapid drug codeine, dihydromorphine, dimenoxadol, dimepheptanol, introduction into the bloodstream. dimethylthiambutene, dioxaphetyl butyrate, dipipanone, 0005. Several methods have been developed to inhibit eptazocine, ethoheptazine, ethylmethylthiamhutene, ethyl drug diversion. One such method involved the incorporation morphine, etonitaZene, etorphine, dihydroetorphine, fenta of the target drug into a polymer matrix. The idea was to nyl, hydrocodone, hydromorphone, hydroxypethidine, adsorb drug within the polymer matrix, which would only isomethadone, ketobemidone, levorphanol, levophena.cyl allow its slow release upon introduction to a solvent. In other morphan, lofentanil, meperidine, meptazinol, metazocine, words, one could not directly access the incorporated drug, methadone, metopon, morphine, myrophine, narceline, nico even through an extraction process. This strategy ultimately morphine, norlevorphanol, normethadone, nalorphine, nal failed, however, when diverters discovered that they could buphene, normorphine, norpipanone, opium, oxycodone, simply crush the polymer matrix, which provided ready oxymorphone, papaveretum, pentazocine, phenadoxone, access to the adsorbed drug. phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, pro 0006 There is accordingly a need for a novel method for poxyphene, Sufentanil, tilidine, tramadol, pharmaceutically inhibiting or preventing drug diversion. That is an object of acceptable salts thereof, stereoisomers thereof, ethers the present invention. thereof, esters thereof, and mixtures thereof. SUMMARY OF INVENTION 0012 Examples of other drugs that may be incorporated into ceramic structures include, without limitation, the, 0007. The present invention is directed to drug? ceramic following: acetorphine, alphacetylmethadol, alphameprod structure combinations that provide drug delivery while ine, alphamethadol, alphaprodine, aenzethidine, betacetyl resisting methods of diversion. The ceramic structure typi methadol, betameprodine, betamethadol, betaprodine, bufo cally includes a metal oxide, wherein the oxide is of tita tenine, carfentanil, diamorphine, diethylthiambutene, nium, Zirconium, Scandium, cerium, or yttrium. Any Suitable difenoxin, dihydrocodeinone, drotebanol, eticyclidine, etox drug may be used in the combinations, but opioid agonists eridine, etryptanrine, furethidine, hydromoiphinol, are preferred, especially oxycodone. levomethorphan, levomoramide, methadyl acetate, meth 0008. In a composition aspect of the present invention, a yldesorphin, methyldihydroniorphine, morpheridine, nora composition comprising a ceramic structure and a drug is cymethadol, pethidine, phenadoxone, phenampromide, provided. The ceramic structure is roughly spherical and phencyclidine, psilocin, racemethorphan, racemoramide, hollow. The drug is coated in the hollow portion of the racemorphan, rolicyclidine, tenocyclidine, thebacon, the ceramic structure, and the mean diameter of the structure baine, tilidate, trimeperidine, acetyldihydrocodeine, ranges from 10 nm to 100 um. The mean particle diameter amphetamine, glutethimide, lefetamine, mecloqualone, oftentimes ranges according to the following: 10 nm to 100 methaqualone, methcathinone, methylamphetamine, meth nm, 101 nm to 200 nmi; 201 nm to 300 nmi; 301 nm to 400 ylphenidate, methylphenobarbitone, nicocodine, nicodicod US 2006/0127486 A1 Jun. 15, 2006 inc, norcodeine, phenmetrazine, pholcodine, propiram, following: 10 nm to 100 nm, 101 nm to 200 nmi; 201 nm to Zipeprol, alprazolam, a minorex, benzphetamine, bro 300 nmi; 301 nm to 400 nmi; 401 nm to 500 nm, 501 nm to mazepam., brotizolam, camazepam, cathine, cathinone, 600 nm, 601 nm to 700 nm, 701 nm to 800 nm, 801 nm to ehlordiazepoxide, chlorphentermine, clobazam, elon 900 nm, 901 nm to 1 um; 1 um to 10 um; 11 um to 25um; azepam, cloraZepic acid, clotiazepam, cloxazolam, and, 26 um to 100 um. delorazepam, dextropropoxyphene, diazepam, diethylpro pion, estaZolarn, ethchlorVynol, ethinamate, ethyl loflaze 0017 Variation in particle size throughout a sample is pate, fencamfamin, fenethylline, fenproporex, fludiazepam, typically well-controlled. For instance, variation is typically flunitrazepam, flurazepam, halazepam, haloxazolam, keta less than 10.0% of the mean diameter, preferably less than Zolam, loprazolam, lorazepam, lormetazepam, mazindol, 7.5% of the mean diameter, and more preferably less than medazepam, mefenorex, mephentermine, meprobamate, 5.0% of the mean diameter. mesocarb, methyprylone, midazolam, nimetaz.epam, 0018 Surface area of the ceramic structures depends on nitrazepam, nordazepam, oxazepam, oxazolam, pemoline, several factors, including particle shape, particle size, and phendimetrazine, phentermine, pinazeparn, pipadrol, particle porosity. Typically, the Surface area of roughly praZeparn, pyrovalerone, temazepam, tetrazepam, triazolam, spherical particles ranges from 0.1 m/g to 100 m/g. The N-ethylamphetamine, atameStane, bolandiol, bolasterone, surface area oftentimes, however, ranges from 0.5 m/g to 50 bolazine, boldenone, bolenol, bolmantalate, calusterone, m?g. 4-chloromethandienone, clostebol, drostanolone, enestebol, epitioStanol, ethyloestrenol, fluoxymesterone, formebolone, 0019 Wall thicknesses of hollow particles tend to range furazabol, mebolazine, mepitioStane, mesabolone, from 10 nm to 5 um, with a range of 50 nm to 3 um being mestarolone, mesterolone, methandienone, methandriol, typical. Pore sizes of such particles further range from 1 nm methenolone,
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • A10 Anabolic Steroids Hardcore Info
    CONTENTS GENERAL INFORMATION 3 Anabolic steroids – What are they? 4 How do they Work? – Aromatisation 5 More molecules – More problems 6 The side effects of anabolic steroids 7 Women and anabolic steroids 8 Injecting steroids 9 Abscesses – Needle Exchanges 10 Intramuscular injection 11 Injection sites 12 Oral steroids – Cycles – Stacking 13 Diet 14 Where do steroids come from? Spotting a counterfeit 15 Drug Information – Drug dosage STEROIDS 16 Anadrol – Andriol 17 Anavar – Deca-Durabolin 18 Dynabolon – Durabolin – Dianabol 19 Esiclene – Equipoise 20 Primobolan Depot – Proviron – Primobolan orals – Pronobol 21 Sustanon – Stromba, Strombaject – Testosterone Cypionate Testosterone Enanthate 22 Testosterone Propionate – Testosterone Suspension 23 Trenbolone Acetate – Winstrol OTHER DRUGS 24 Aldactone – Arimidex 25 Clenbuterol – Cytomel 26 Ephedrine Hydrochloride – GHB 27 Growth Hormone 28 Insulin 30 Insulin-Like Growth Factor-1 – Human Chorionic Gonadotrophin 31 Tamoxifen – Nubain – Recreational Drugs 32 Steroids and the Law 34 Glossary ANABOLIC STEROIDS People use anabolic steroids for various reasons, some use them to build muscle for their job, others just want to look good and some use them to help them in sport or body building. Whatever the reason, care needs to be taken so that as little harm is done to the body as possible because despite having muscle building effects they also have serious side effects especially when used incorrectly. WHAT ARE THEY? Anabolic steroids are man made versions of the hormone testosterone. Testosterone is the chemical in men responsible for facial hair, deepening of the voice and sex organ development, basically the masculine things Steroids are in a man. used in medicine to treat anaemia, muscle weakness after These masculine effects surgery etc, vascular are called the androgenic disorders and effects of testosterone.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Control Substance List
    Drugs DrugID SubstanceName DEANumbScheNarco OtherNames 1 1-(1-Phenylcyclohexyl)pyrrolidine 7458 I N PCPy, PHP, rolicyclidine 2 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine 9663 I Y PEPAP, synthetic heroin 3 1-[1-(2-Thienyl)cyclohexyl]piperidine 7470 I N TCP, tenocyclidine 4 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine 7473 I N TCPy 5 13Beta-ethyl-17beta-hydroxygon-4-en-3-one 4000 III N 6 17Alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane 4000 III N 7 17Alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane 4000 III N 8 17Alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene 4000 III N 9 17Alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hyd 4000 III N 10 17Alpha-methyl-delta1-dihydrotestosterone (17beta-hydroxy- 4000 III N 17-Alpha-methyl-1-testosterone 11 19-Nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene; 4000 III N 12 19-Nor-4-androstenedione (estr-4-en-3,17-dione) 4000 III N 13 19-Nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene; 4000 III N 14 19-Nor-5-androstenedione (estr-5-en-3,17-dione) 4000 III N 15 1-Androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1- 4000 III N 16 1-Androstenedione (5alpha-androst-1-en-3,17-dione) 4000 III N 17 1-Methyl-4-phenyl-4-propionoxypiperidine 9661 I Y MPPP, synthetic heroin 18 1-Phenylcyclohexylamine 7460 II N PCP precursor 19 1-Piperidinocyclohexanecarbonitrile 8603 II N PCC, PCP precursor 20 2,5-Dimethoxy-4-(n)-propylthiophenethylamine 7348 I N 2C-T-7 21 2,5-Dimethoxy-4-ethylamphetamine 7399 I N DOET 22 2,5-Dimethoxyamphetamine 7396 I N DMA, 2,5-DMA 23 3,4,5-Trimethoxyamphetamine
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • 159 Misuse of Drugs (Controlled Drugs) Order 2001
    MISUSE OF DRUGS (CONTROLLED DRUGS) ORDER 2001 BR 37/2001 MISUSE OF DRUGS ACT 1972 1972 : 159 MISUSE OF DRUGS (CONTROLLED DRUGS) ORDER 2001 The Minister of Health and Family Services, in exercise of the powers conferred on him by section 3(2) of the Misuse Of Drugs Act 1972, makes the following Order: Citation 1 This Order may be cited as the Misuse Of Drugs (Controlled Drugs) Order 2001. Amendment of Schedule 2 to Act No. 159 of 1972 2 Part I of Schedule 2 to the Misuse of Drugs Act 1972 is deleted and the new Part I set forth in the Schedule to this Order is substituted. Commencement 3 This Order commences on 1st August, 2001. SCHEDULE 2 (paragraph 2) PART I 1. The following substances and products, namely:- (a) ACETORPHINE ACETYLDIHYDROCODEINE ALFENTANIL ALLYLPRODINE ALPHACETYLMETHADOL 1989 Revision 1 MISUSE OF DRUGS (CONTROLLED DRUGS) ORDER 2001 ALPHAMEPRODINE ALPHAMETHADOL ALPHAPRODINE ALPRAZOLAM AMPHETAMINE ANILERIDINE ATAMESTANE BENZETHIDINE BENZPHETAMINE BENZYLMORPHINE (3-Benzylmorphine) BETACETYLMETHADOL BETAMEPRODINE BETAMETHADOL BETAPRODINE BEZITRAMIDE BOLANDIOL BOLASTERONE BOLAZINE BOLDENONE BOLENOL BOLMANTALATE BROMAZEPAM BUFOTENINE BUPRENORPHINE CALUUSTERONE CAMAZEPAM CANNABINOL DERIVATIVES CANNABINOL except where contained in Cannabis or Cannabis resin CANNABIS AND CANNABIS RESIN CARFENTANIL CATHINE CATHINONE CHLORDIAZEPOXIDE CHLORPHENTERMINE 4-CHLOROMETHANDIENONE CHORIONIC GONADOTROPHIN (HCG) and NON-HUMAN CHORIONIC GONADOTROPHIN CLENBUTEROL CLOBAZAM CLONAZEPAM CLONITAZENE CLORAZEPIC ACID CLOSTEBOL 2 1989 Revision MISUSE
    [Show full text]
  • Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3Rd Floor Seacole Building 2
    ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3rd Floor Seacole Building 2. Marsham Street London SW1P 4DF 020 7035 0454 Email: [email protected] Rt Hon. Theresa May MP Home Office 2 Marsham Street London SW1P 4DF 18th October 2012 Dear Home Secretary, In March 2012 the ACMD advised that methoxetamine be subject to a temporary class drug order. Methoxetamine was marketed as a legal alternative to ketamine until a temporary class drug order was implemented in April 2012. As is now required, the ACMD has followed its initial assessment with a consideration of methoxetamine in the context of the Misuse of Drugs Act 1971; I enclose the report with this letter. The chemical structure of methoxetamine bears a close resemblance to that of both ketamine and phencyclidine (PCP, „Angel Dust‟, a class A drug), which both produce well- documented and serious adverse effects following both acute and chronic usage. Users report that the effects of methoxetamine are similar to those of ketamine, however, some users report that the effects are of longer duration.The harmful effects reported include severe dissociation, cardiovascular symptoms, paranoid thoughts and unpleasant hallucinations. The first analytically confirmed series reported by Guy‟s and St Thomas‟ NHS Foundation Trust, London in 2011, was of three individuals who presented having self-reported use of methoxetamine. All three presented with a ketamine-like dissociative state, but also had significant stimulant effects with agitation and cardiovascular effects including tachycardia and hypertension. Toxicological screening of serum samples confirmed methoxetamine use in two of the cases.
    [Show full text]
  • Designer Drugs: a Review
    WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Chavan et al. World Journal of Pharmacy and Pharmaceutical Sciences SJIF Impact Factor 5.210 Volume 4, Issue 08, 297-336. Review Article ISSN 2278 – 4357 DESIGNER DRUGS: A REVIEW Dr. Suyash Chavan,MBBS*1 and Dr. Vandana Roy2 1MD, Resident Doctor, Department of Pharmacology, Maulana Azad Medical College, New Delhi. 2MD, PhD Professor, Department of Pharmacology, Maulana Azad Medical College, New Delhi. ABSTRACT Article Received on 25 May 2015, Designer drugs‟ are psychoactive substances that mimic the effects of Revised on 16 June 2015, other banned illicit drugs but evade detection by law enforcing Accepted on 07 July 2015 agencies. This is because of modifications in the structure of the original psychoactive molecule. Originally developed as a way to *Correspondence for evade existing drug laws in the late 1960s, the synthesis and use of Author designer drugs has increased dramatically. They are advertised with Dr. Suyash Chavan innocuous names and are sold mostly over the internet, discreet outlets MD, Resident Doctor, Department of and at entertainment clubs. Victims may exhibit symptoms similar to Pharmacology, Maulana the effects of the illegal drug that these synthetic drugs mimic, Azad Medical College, however, the exact culprit drug is not detected due to structural New Delhi. modifications in the new drug. Overdose of these drugs may lead to serious adverse effects that can be life threatening. Understanding the pharmacology and toxicology of these agents is essential to facilitate their detection and to provide better medical care for patients suffering from adverse effects due to their consumption.
    [Show full text]